Investing

Today's Standout Winners and Losers

The Dow Jones Industrial Average, Nasdaq and S&P 500 are all down more than 1% Thursday morning, with banks and health insurance stocks down the most in the broader market. Nevertheless, the big winners and losers today are not in either of those markets. Rather, a mix of pharmaceutical and devicemakers were the biggest fluctuators, along with a mining and electronics firm.

Here are the big winners and losers for Thursday:

Biggest Winners

Shares of Synergetics USA (NASDAQ: SURG) are up 31.81% to $5.10  on trading volume of 1.3 million shares. The FDA on Wednesday approved VersaVIT- a device to remove liquid during eye surgey. The stock is still well down of its 52-week high of $7.55.

Shares of Orexigen Therapeutics (NASDAQ: OREX) are up 9.52% to $5.38  on trading volume of 9.1 million shares. The FDA approved competitor Arena Pharmaceuticals’ obesity durg, Belviq, stirring optimism that regulators will also approve Orexigen’s weight loss drug, Contrave. Shares are trading near the 52-week high of $5.57.

Biggest Losers

Shares of Anthera Pharmaceuticals (NASDAQ: ANTH) are down 66.92% to 90 cents on trading volume of 8.2 million shares. The company reported mixed results in a clinical trial for its drug to treat lupus, blisibimod. Before Thursday, the 52-week low was $1.44.

Shares of Tahoe Resources (NYSE: TAHO) are down 23.73% to $12.05  on trading volume of 3.3 million shares. The stock dropped after Reuters reported that Guatemala may look to tighten its mining laws. Before Thursday, the 52-week low was $12.96.

Shares of Orbotech (NASDAQ: ORBK) are down 18.66% to $7.67 on trading volume of 1.1 million shares. The company revised its full-year revenue outlook to between $430 million and $450 million, down from $500 million. The firm is facing charges in South Korea of misuse of confidential customer information, resulting in added expenses. Before Thursday, the 52-week low  was $7.65.

Samuel Weigley

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.